SEOM clinical guidelines for the treatment of head and neck cancer (2020)
-
R. Mesia [1] ; L. Iglesias [2] ; J. Lambea [3] ; J. Martínez-Trufero [4] ; A. Soria [5] ; M. Taberna [1] ; J. Trigo [7] ; M. Chaves [8] ; A. García-Castaño [6] ; J. Cruz [9]
-
[1] Institute Catalá Oncología
Institute Catalá Oncología
Barcelona, España
-
[2] Hospital Universitario 12 de Octubre
Hospital Universitario 12 de Octubre
Madrid, España
-
[3] Hospital Clínico Universitario Lozano Blesa
Hospital Clínico Universitario Lozano Blesa
Zaragoza, España
-
[4] Hospital Miguel Servet
Hospital Miguel Servet
Zaragoza, España
-
[5] Hospital Ramón y Cajal
Hospital Ramón y Cajal
Madrid, España
-
[6] Hospital Universitario Marqués de Valdecilla
Hospital Universitario Marqués de Valdecilla
Santander, España
-
[7] Hospital Clínico Virgen de la Victoria
-
[8] Hospital Virgen de Valme
-
[9] Hospital Clínico Universitario de Salamanca
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 5 (May), 2021 (Ejemplar dedicado a: SEOM clinical guidelines 2020), págs. 913-921
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Head and neck cancers (HNC) are defined as malignant tumours located in the upper aerodigestive tract and represents 5% of oncologic cases in adults in Spain. More than 90% of these tumours have squamous histology. In an effort to incorporate evidence obtained since 2017 publication, the Spanish Society of Medical Oncology (SEOM) presents an update of the squamous cell HNC diagnosis and treatment guideline. Most relevant diagnostic and therapeutic changes from the last guideline have been updated: introduction of sentinel node biopsy in early oral/oropharyngeal cancer treated with surgery, concomitant radiotherapy with weekly cisplatin 40 mg/m2 in the adjuvant setting, new approaches for HPV-related oropharyngeal cancer and new treatments with immune-checkpoint inhibitors in recurrent/metastatic disease.
